CHATSWORTH, Calif., July 13, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS) a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced a new supply agreement for its full product line of automated and semi-automated urinalysis systems, related products, consumables and services agreements, with Amerinet Inc., a leading national healthcare group purchasing organization (GPO) servicing more than 41,000 provider facilities, including 2,537 acute care hospitals. The new three-year sales and service supply agreement went into effect June 1, 2010.
"We are pleased to renew our supply agreement with Amerinet, one of the largest GPOs in the country. Since beginning our partnership with Amerinet in June 2007, the installed base of IRIS instrumentation within the Amerinet membership has grown by more than 400%, representing a vital sales channel for our urinalysis systems and consumables," stated Thomas E. Warekois, President of the Iris Diagnostics Division. "We look forward to continuing our strong strategic partnership with Amerinet in the years ahead, and to bringing laboratory automation to an increasing number of its members," he added.
About Amerinet Inc.
As a leading national healthcare group purchasing organization, Amerinet strategically partners with acute and alternate care providers to reduce costs and improve quality through its performance solutions. Built on a foundation of data, savings and trust, and supported by a team of clinical and supply chain experts, Amerinet enriches healthcare delivery for its members and the communities they serve. To learn more about the Amerinet difference, visit http://www.amerinet-gpo.com.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,700 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA®, platform, with applications in oncology and infectious disease. For more information, visit www.proiris.com.